Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch

Hiroaki Nagano, Masato Sakon, Hidetoshi Eguchi, Motoi Kondo, Tameyoshi Yamamoto, Hideo Ota, Masato Nakamura, Hiroshi Wada, Bazarragcha Damdinsuren, Shigeru Marubashi, Atsushi Miyamoto, Yutaka Takeda, Keizo Dono, Koji Umeshita, Shoji Nakamori, Morito Monden

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background/Aims: The prognosis of hepatocellular carcinoma (HCC) invading the major branches of the portal vein (Vp3) is extremely poor. Recently, we reported the efficacy of combination therapy with subcutaneous interferon (IFN)-alpha and intra-arterial 5-FU for intractable HCC with Vp3. In this study, this therapy was applied for resectable advanced HCC (Vp3) as a postoperative adjuvant. Methodology: Patients with HCC and tumor thrombi either in the major or first branch of portal vein were included (n = 30). Fifteen consecutive patients with HCC and Vp3 were treated with at least 3 cycles of a combination therapy consisting of continuous arterial infusion of 5-FU (300mg/mm 3/ day, 5 days/week, for the initial 2 weeks) and subcutaneous injection of IFN (5 MIU, 3 times/week, 4 weeks) as a postoperative adjuvant therapy following hepatic resection. Another 15 patients who underwent hepatic resection with no IFN/5-FU chemotherapy acted as controls. Results: The results were as follows in the IFN/5-FU adjuvant treatment group; disease-free survival (n = 11,5-55 months), survival with recurrence (n = 2, 9, 48 months), cancer death (n = 1, 18 months), death from other causes but no recurrence (n = 1, 22 months). The 1-year survival rate was 100% in patients treated with IFN/5-FU, and 41% in those without IFN/5-FU historical controls (n = 15). There was a significant difference in disease-free and overall survival rates between the two groups (p = 0.0033 and 0.0031). Conclusions: Combination therapy with subcutaneous IFN and intra-arterial perfusion of 5-FU seems to be a promising postoperative adjuvant treatment modality for resectable HCC with Vp3.

Original languageEnglish
Pages (from-to)172-179
Number of pages8
JournalHepato-gastroenterology
Volume54
Issue number73
Publication statusPublished - Jan 1 2007
Externally publishedYes

Fingerprint

Fluorouracil
Interferons
Hepatocellular Carcinoma
Thrombosis
Liver
Neoplasms
Portal Vein
Therapeutics
Disease-Free Survival
Survival Rate
Recurrence
Subcutaneous Injections
Interferon-alpha
Cause of Death
Perfusion
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Nagano, H., Sakon, M., Eguchi, H., Kondo, M., Yamamoto, T., Ota, H., ... Monden, M. (2007). Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepato-gastroenterology, 54(73), 172-179.

Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. / Nagano, Hiroaki; Sakon, Masato; Eguchi, Hidetoshi; Kondo, Motoi; Yamamoto, Tameyoshi; Ota, Hideo; Nakamura, Masato; Wada, Hiroshi; Damdinsuren, Bazarragcha; Marubashi, Shigeru; Miyamoto, Atsushi; Takeda, Yutaka; Dono, Keizo; Umeshita, Koji; Nakamori, Shoji; Monden, Morito.

In: Hepato-gastroenterology, Vol. 54, No. 73, 01.01.2007, p. 172-179.

Research output: Contribution to journalArticle

Nagano, H, Sakon, M, Eguchi, H, Kondo, M, Yamamoto, T, Ota, H, Nakamura, M, Wada, H, Damdinsuren, B, Marubashi, S, Miyamoto, A, Takeda, Y, Dono, K, Umeshita, K, Nakamori, S & Monden, M 2007, 'Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch', Hepato-gastroenterology, vol. 54, no. 73, pp. 172-179.
Nagano, Hiroaki ; Sakon, Masato ; Eguchi, Hidetoshi ; Kondo, Motoi ; Yamamoto, Tameyoshi ; Ota, Hideo ; Nakamura, Masato ; Wada, Hiroshi ; Damdinsuren, Bazarragcha ; Marubashi, Shigeru ; Miyamoto, Atsushi ; Takeda, Yutaka ; Dono, Keizo ; Umeshita, Koji ; Nakamori, Shoji ; Monden, Morito. / Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. In: Hepato-gastroenterology. 2007 ; Vol. 54, No. 73. pp. 172-179.
@article{a043e53bece34987b1abcef98a9a7c8e,
title = "Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch",
abstract = "Background/Aims: The prognosis of hepatocellular carcinoma (HCC) invading the major branches of the portal vein (Vp3) is extremely poor. Recently, we reported the efficacy of combination therapy with subcutaneous interferon (IFN)-alpha and intra-arterial 5-FU for intractable HCC with Vp3. In this study, this therapy was applied for resectable advanced HCC (Vp3) as a postoperative adjuvant. Methodology: Patients with HCC and tumor thrombi either in the major or first branch of portal vein were included (n = 30). Fifteen consecutive patients with HCC and Vp3 were treated with at least 3 cycles of a combination therapy consisting of continuous arterial infusion of 5-FU (300mg/mm 3/ day, 5 days/week, for the initial 2 weeks) and subcutaneous injection of IFN (5 MIU, 3 times/week, 4 weeks) as a postoperative adjuvant therapy following hepatic resection. Another 15 patients who underwent hepatic resection with no IFN/5-FU chemotherapy acted as controls. Results: The results were as follows in the IFN/5-FU adjuvant treatment group; disease-free survival (n = 11,5-55 months), survival with recurrence (n = 2, 9, 48 months), cancer death (n = 1, 18 months), death from other causes but no recurrence (n = 1, 22 months). The 1-year survival rate was 100{\%} in patients treated with IFN/5-FU, and 41{\%} in those without IFN/5-FU historical controls (n = 15). There was a significant difference in disease-free and overall survival rates between the two groups (p = 0.0033 and 0.0031). Conclusions: Combination therapy with subcutaneous IFN and intra-arterial perfusion of 5-FU seems to be a promising postoperative adjuvant treatment modality for resectable HCC with Vp3.",
author = "Hiroaki Nagano and Masato Sakon and Hidetoshi Eguchi and Motoi Kondo and Tameyoshi Yamamoto and Hideo Ota and Masato Nakamura and Hiroshi Wada and Bazarragcha Damdinsuren and Shigeru Marubashi and Atsushi Miyamoto and Yutaka Takeda and Keizo Dono and Koji Umeshita and Shoji Nakamori and Morito Monden",
year = "2007",
month = "1",
day = "1",
language = "English",
volume = "54",
pages = "172--179",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "73",

}

TY - JOUR

T1 - Hepatic resection followed by IFN-α and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch

AU - Nagano, Hiroaki

AU - Sakon, Masato

AU - Eguchi, Hidetoshi

AU - Kondo, Motoi

AU - Yamamoto, Tameyoshi

AU - Ota, Hideo

AU - Nakamura, Masato

AU - Wada, Hiroshi

AU - Damdinsuren, Bazarragcha

AU - Marubashi, Shigeru

AU - Miyamoto, Atsushi

AU - Takeda, Yutaka

AU - Dono, Keizo

AU - Umeshita, Koji

AU - Nakamori, Shoji

AU - Monden, Morito

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Background/Aims: The prognosis of hepatocellular carcinoma (HCC) invading the major branches of the portal vein (Vp3) is extremely poor. Recently, we reported the efficacy of combination therapy with subcutaneous interferon (IFN)-alpha and intra-arterial 5-FU for intractable HCC with Vp3. In this study, this therapy was applied for resectable advanced HCC (Vp3) as a postoperative adjuvant. Methodology: Patients with HCC and tumor thrombi either in the major or first branch of portal vein were included (n = 30). Fifteen consecutive patients with HCC and Vp3 were treated with at least 3 cycles of a combination therapy consisting of continuous arterial infusion of 5-FU (300mg/mm 3/ day, 5 days/week, for the initial 2 weeks) and subcutaneous injection of IFN (5 MIU, 3 times/week, 4 weeks) as a postoperative adjuvant therapy following hepatic resection. Another 15 patients who underwent hepatic resection with no IFN/5-FU chemotherapy acted as controls. Results: The results were as follows in the IFN/5-FU adjuvant treatment group; disease-free survival (n = 11,5-55 months), survival with recurrence (n = 2, 9, 48 months), cancer death (n = 1, 18 months), death from other causes but no recurrence (n = 1, 22 months). The 1-year survival rate was 100% in patients treated with IFN/5-FU, and 41% in those without IFN/5-FU historical controls (n = 15). There was a significant difference in disease-free and overall survival rates between the two groups (p = 0.0033 and 0.0031). Conclusions: Combination therapy with subcutaneous IFN and intra-arterial perfusion of 5-FU seems to be a promising postoperative adjuvant treatment modality for resectable HCC with Vp3.

AB - Background/Aims: The prognosis of hepatocellular carcinoma (HCC) invading the major branches of the portal vein (Vp3) is extremely poor. Recently, we reported the efficacy of combination therapy with subcutaneous interferon (IFN)-alpha and intra-arterial 5-FU for intractable HCC with Vp3. In this study, this therapy was applied for resectable advanced HCC (Vp3) as a postoperative adjuvant. Methodology: Patients with HCC and tumor thrombi either in the major or first branch of portal vein were included (n = 30). Fifteen consecutive patients with HCC and Vp3 were treated with at least 3 cycles of a combination therapy consisting of continuous arterial infusion of 5-FU (300mg/mm 3/ day, 5 days/week, for the initial 2 weeks) and subcutaneous injection of IFN (5 MIU, 3 times/week, 4 weeks) as a postoperative adjuvant therapy following hepatic resection. Another 15 patients who underwent hepatic resection with no IFN/5-FU chemotherapy acted as controls. Results: The results were as follows in the IFN/5-FU adjuvant treatment group; disease-free survival (n = 11,5-55 months), survival with recurrence (n = 2, 9, 48 months), cancer death (n = 1, 18 months), death from other causes but no recurrence (n = 1, 22 months). The 1-year survival rate was 100% in patients treated with IFN/5-FU, and 41% in those without IFN/5-FU historical controls (n = 15). There was a significant difference in disease-free and overall survival rates between the two groups (p = 0.0033 and 0.0031). Conclusions: Combination therapy with subcutaneous IFN and intra-arterial perfusion of 5-FU seems to be a promising postoperative adjuvant treatment modality for resectable HCC with Vp3.

UR - http://www.scopus.com/inward/record.url?scp=34047129082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047129082&partnerID=8YFLogxK

M3 - Article

VL - 54

SP - 172

EP - 179

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 73

ER -